Hangzhou, China

Sciwind Biosciences

Chinese biopharmaceutical company focused on weight management and metabolic disease. It developed ecnoglutide, a long-acting GLP-1 receptor agonist that the company describes as cAMP-biased, which China's regulator approved in 2026 for type 2 diabetes and for chronic weight management. Sciwind has licensing partnerships for the drug in China and in other regions.

Ecnoglutide approval for type 2 diabetes (China)

Sciwind announced on 2026-01-30 that China's NMPA had approved ecnoglutide injection for glycemic control in adults with type 2 diabetes.[src]

Ecnoglutide approval for weight management (China)

Sciwind announced on 2026-03-06 that the NMPA had approved ecnoglutide injection for chronic weight management in Chinese adults with overweight or obesity.[src]

Pfizer China commercialisation agreement

Announced 2026-02-24: Pfizer obtains exclusive commercialization rights for ecnoglutide in Mainland China. Sciwind states it remains the Marketing Authorization Holder and is responsible for research and development, registration, manufacturing and supply, and is eligible for up to US$495 million in upfront, regulatory and sales milestone payments.[src]

Other territories (company-listed agreements)

Sciwind's partnerships page lists a licence with HK inno.N Corporation for ecnoglutide in South Korea (announced 2024-05-07) and a global licensing and collaboration agreement with Verdiva Bio Limited for a metabolic portfolio outside Greater China and South Korea (announced 2025-01-10).[src]